In a study of 13 women with advanced-stage ovarian cancer, 14 with early-stage ovarian cancer, 14 with benign ovarian tumors, and 39 healthy women, serum FGF23 levels were higher in patients with advanced-stage ovarian cancer, without decreased serum phosphate levels (24). The gene discussed is FGF23; the disease is ovarian benign neoplasm.